| __timestamp | Bio-Techne Corporation | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 33534999 |
| Thursday, January 1, 2015 | 144969000 | 1982000 |
| Friday, January 1, 2016 | 162364000 | 2438000 |
| Sunday, January 1, 2017 | 188462000 | 2901000 |
| Monday, January 1, 2018 | 210850000 | 2423000 |
| Tuesday, January 1, 2019 | 240515000 | 24212000 |
| Wednesday, January 1, 2020 | 255497000 | 39872000 |
| Friday, January 1, 2021 | 298182000 | 44152000 |
| Saturday, January 1, 2022 | 349103000 | 55126000 |
| Sunday, January 1, 2023 | 366887000 | 65573000 |
| Monday, January 1, 2024 | 389335000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the cost of revenue for Insmed Incorporated and Bio-Techne Corporation from 2014 to 2023. Over this period, Bio-Techne Corporation has consistently demonstrated a robust growth trajectory, with its cost of revenue increasing by approximately 266%, from $106 million in 2014 to an impressive $389 million in 2023. This reflects the company's expanding operations and market reach.
Conversely, Insmed Incorporated, while smaller in scale, has shown remarkable growth, with its cost of revenue surging by over 1,850%, from a modest $3.35 million in 2014 to $65.57 million in 2023. This dramatic increase underscores Insmed's aggressive expansion and investment in its product pipeline. Notably, data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting in this sector.
Amgen Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Gilead Sciences, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Gilead Sciences, Inc. and Bio-Techne Corporation's Expenses
Takeda Pharmaceutical Company Limited vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
United Therapeutics Corporation vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Insmed Incorporated and Catalent, Inc.'s Expenses
Insmed Incorporated vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Jazz Pharmaceuticals plc
Cost of Revenue Comparison: Insmed Incorporated vs Xenon Pharmaceuticals Inc.
Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Viridian Therapeutics, Inc.